Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Key facts

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Principal Investigator

Jaishri Blakeley, MD

Johns Hopkins University

Intervention

Nivolumab(drug)

Enrollment

13 target

Eligibility

12-100 years · All sexes

Timeline

2021 – 2025

Study locations (1)

• Johns Hopkins Medical Institution, Baltimore, Maryland, United States

Collaborators

Bristol-Myers Squibb · Congressionally Directed Medical Research Programs · Cancer Research and Biostatistics Clinical Trials Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant peripheral nerve sheath tumor

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT06693284
  A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
  University of Minnesota
• RECRUITINGPHASE2NCT04872543
  A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE1NCT04222413
  Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
  National Cancer Institute (NCI)
• ACTIVE NOT RECRUITINGPHASE2NCT03872427
  Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
  National Cancer Institute (NCI)
• RECRUITINGNANCT03141021
  Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
  Washington University School of Medicine

See all trials for Malignant peripheral nerve sheath tumor →